Cannabis Science Reports Second Cancer Patient Receives Clean Biopsy Report Confirming the Biopsy is Free of Cancer Cells
April 04 2012 - 1:12PM
Business Wire
Cannabis Science, Inc. (OTCBB: CBIS) a pioneering U.S. biotech
company developing pharmaceutical cannabis (marijuana) products is
happy to report that patient #2, who had a Squamous cell carcinoma
on her arm, has received her biopsy report. It confirms what was
visually apparent from the photo-documentation on our website. Her
biopsy was free of cancer cells and she will not need any surgical
procedure. Nevertheless, the patient will continue with her
self-administered topical application of extracts for a while
longer to minimize any chance of any surviving cancer cells in
areas beyond what was biopsied.
Cannabis Science Inc., President & CEO, Dr. Robert Melamede
Ph.D., stated, “Squamous cell carcinomas have a much greater
invasive potential than is typical of basal cell carcinomas.
Photo-documentation of topical cannabis extract treatments of
patient #2 and patient #3 dramatically demonstrate how the
treatment appear to extrude the subcutaneous tumor to the surface
as the killing and subsequent healing proceeds. Patient #3 reports
continued progress as his tumors appear to shrink and the pain
levels continue to improve. The patient's wife commented that about
75% of the large tumor mass is gone. We will continue with ‘live
updates’ as new pictures and physician reports are made available
to us.”
You can view the patient’s photographs during the treatment
process, as well as the full biopsy report from the physician, on
the Cannabis Science website www.cannabisscience.com. Click the
button “View Images of 2nd Self-Medicated Patient & The
Apparent Success” to view the full biopsy report, photos and
additional information.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The second
formulations will address the needs of patients choosing to use
concentrated cannabis extracts to treat their ailments. Eventually,
all Americans will have access to a safe and effective FDA approved
medicine regardless of which state they live in. To maintain that
marijuana is a dangerous, addictive drug with no medical value is
scientifically absurd. Cannabis medicines, with no effective lethal
dose, are far safer than aspirin, acetaminophen, and most other OTC
drugs that kill thousands of Americans every year. The Company
works with world authorities on phytocannabinoid science targeting
critical illnesses, and adheres to scientific methodologies to
develop, produce and commercialize phytocannabinoid-based
pharmaceutical products. In sum, we are dedicated to the creation
of cannabis-based medicines, both with and without psychoactive
properties, to treat disease and the symptoms of disease, as well
as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
works such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does
it intend to update the results of these forward-looking
statements.